Coeptis Therapeutics Holdings, Inc.Coeptis Therapeutics Holdings, Inc.Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc.

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪68.11 M‬USD
−3.9491USD
‪−10.88 M‬USD
0.00USD
‪5.11 M‬
Beta (1Y)
3.91

About Coeptis Therapeutics Holdings, Inc.


CEO
David Mehalick
Headquarters
Wexford
Founded
2017
Identifiers
3
ISIN US19207A1161
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Displays a symbol's price movements over previous years to identify recurring trends.